FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED (FPH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

FPH

FPH - FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.39
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

Fisher & Paykel Healthcare is a designer and manufacturer of systems used in respiratory care and treatment of sleep disorders. It was separated from Fisher & Paykel and listed on the ASX and NZX in 2001. A brief Nasdaq listing was terminated in 2003. Only 1% of its revenues stems from New Zealand.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$32.64

02 May
2025

0.340

OPEN

$32.11

1.05%

HIGH

$32.76

787,691

LOW

$31.84

OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
FPH: 1
Title FY25
Forecast		 FY26
Forecast
EPS (cps) 55.5 xxx
DPS (cps) 41.3 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 59.0 xxx
Dividend Yield 1.3% xxx
Div Pay Ratio(%) 74.5% xxx
This company reports in NZD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.97%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.17

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 05/12 - (franking ex-di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx21.1
DPS All xxxxxxxxxxxxxxx45.3
Sales/Revenue xxxxxxxxxxxxxxx1,629.7 M
Book Value Per Share xxxxxxxxxxxxxxx276.4
Net Operating Cash Flow xxxxxxxxxxxxxxx398.2 M
Net Profit Margin xxxxxxxxxxxxxxx7.54 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx7.56 %
Return on Invested Capital xxxxxxxxxxxxxxx7.12 %
Return on Assets xxxxxxxxxxxxxxx5.92 %
Return on Equity xxxxxxxxxxxxxxx7.56 %
Return on Total Capital xxxxxxxxxxxxxxx19.20 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-30.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx88 M
Long Term Debt xxxxxxxxxxxxxxx85 M
Total Debt xxxxxxxxxxxxxxx173 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx75 M
Price To Book Value xxxxxxxxxxxxxxx8.51

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx314.2 M
Capex % of Sales xxxxxxxxxxxxxxx19.28 %
Cost of Goods Sold xxxxxxxxxxxxxxx647 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx641 M
Research & Development xxxxxxxxxxxxxxx184 M
Investments - Total xxxxxxxxxxxxxxx49 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.3

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

5

xxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

29/11/2024

1

Buy

-

-

Fisher & Paykel Healthcare's outlook looks solid, with UBS projecting CAGR EPS of 25% for the four years starting from FY25, but the share price is already seen reflecting this.

Given its superior growth outlook, the broker also believes Fisher & Paykel Healthcare should retain its valuation premium vis a vis larger cap healthcare sector peers.

The released H1 financials met the broker's forecasts, but underlying revealed multiple differences, including stronger revenues from hospitals, lower revenues from homecare, and also a higher gross margin.

UBS highlights potential US tariffs on Mexican imports could inflict a negative impact, estimated at -2-3% on EPS. Valuation has improved to NZ$38.10 from NZ$36. Buy.

FORECAST
UBS forecasts a full year FY25 dividend of 49.22 cents and EPS of 57.42 cents.
UBS forecasts a full year FY26 dividend of 58.34 cents and EPS of 72.01 cents.

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Goldman Sachs

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

09/04/2025

3

Upgrade to Neutral from Underweight

-

-

The key change in US President Trump's reciprocal tariff announcement last week that has implications for Fisher & Paykel Healthcare was nil tariff on Mexican imports and 10% tariff on NZ imports.

Jarden notes almost all of the company's Mexico imports are compliant with United States–Mexico–Canada Agreement (USMCA), which would mean no tariff. Last month, the broker conducted an analysis on an assumption of a 25% Mexico imports tariff.

The broker's revised estimate suggests the additional cost to the company would be NZ$30m in FY26, down from the previous analysis of NZ$100m. Factoring this into the forecasts, plus exchange rate changes, lowered the FY26 EPS estimate by -3%.

Target lifts to NZ$33.20 from NZ$30.10 on longer-term earnings upgrade and roll forward. Rating upgraded to Neutral from Underweight.

FORECAST
Jarden forecasts a full year FY25 dividend of 38.74 cents and EPS of 58.52 cents.
Jarden forecasts a full year FY26 dividend of 41.93 cents and EPS of 67.36 cents.

Wilsons

xx/xx/xxxx

1

xxxxxxx xx xxxxxxxxxx xxxx xxxxxx xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Extra Coverage Research History >

FPH STOCK CHART

FNArena News on FPH

1
Rudi’s View: Awaiting The Real World Ramifications

Apr 30 2025 - Rudi's View
2
Australian Broker Call *Extra* Edition – Apr 15, 2025

Apr 16 2025 - Daily Market Reports
3
In Case You Missed It – BC Extra Upgrades & Downgrades – 11-04-25

Apr 11 2025 - Weekly Reports
4
In Brief: Tariffs, Healthcare & Wealth Platforms

Apr 11 2025 - Weekly Reports
5
Australian Broker Call *Extra* Edition – Apr 09, 2025

Apr 09 2025 - Daily Market Reports

Latest Medical Equipment & Devices News

1
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
2
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
3
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
4
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
5
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia
6
The Trend Remains Pro Medicus’ Friend

Jan 16 2025 - Technicals
7
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps
8
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
9
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
10
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals